Vyant Bio, Inc. (NASDAQ:VYNT) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 164,100 shares, a drop of 22.4% from the August 15th total of 211,500 shares. Based on an average trading volume of 177,100 shares, the short-interest ratio is currently 0.9 days. Approximately 0.7% of the company’s shares are sold short.
In other Vyant Bio news, Director Paul R. Hansen acquired 20,000 shares of Vyant Bio stock in a transaction dated Thursday, August 19th. The stock was purchased at an average cost of $2.35 per share, for a total transaction of $47,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John A. Roberts acquired 10,406 shares of Vyant Bio stock in a transaction dated Monday, August 23rd. The shares were acquired at an average price of $2.41 per share, with a total value of $25,078.46. The disclosure for this purchase can be found here. Insiders have bought 41,406 shares of company stock valued at $102,218 in the last ninety days. Insiders own 15.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of VYNT. BlackRock Inc. purchased a new position in Vyant Bio in the 1st quarter worth approximately $764,000. Virtu Financial LLC purchased a new position in Vyant Bio in the 1st quarter worth approximately $182,000. Geode Capital Management LLC grew its stake in Vyant Bio by 203.0% in the 2nd quarter. Geode Capital Management LLC now owns 176,680 shares of the company’s stock worth $660,000 after buying an additional 118,375 shares in the last quarter. Vanguard Group Inc. grew its stake in Vyant Bio by 881.6% in the 2nd quarter. Vanguard Group Inc. now owns 839,226 shares of the company’s stock worth $3,139,000 after buying an additional 753,728 shares in the last quarter. Finally, Bank of Montreal Can purchased a new position in Vyant Bio in the 2nd quarter worth approximately $37,000. 7.83% of the stock is currently owned by institutional investors.
Vyant Bio Company Profile
Vyant Bio, Inc is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities.
Further Reading: Trading Strategy
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.